US FDA grants fast track designation to Celladon's Mydicar for heart failure pharmabiz.com The US Food and Drug Administration (FDA) has granted fast track designation to Celladon Corporation's investigational product candidate Mydicar for the treatment of advanced heart failure. The fast track programme of the FDA is designed to facilitate ... |
